(84 days)
Not Found
No
The summary does not mention AI or ML, and the device description focuses on electro-mechanical function and standard software updates.
No
The device is intended to express and collect breast milk, and does not perform any therapeutic function like treating a disease or condition.
No
Explanation: The device's intended use is to express and collect milk from lactating women, which is a therapeutic function, not a diagnostic one. There is no mention of the device providing information about a medical condition or disease.
No
The device description explicitly states it is a "battery-powered electro-mechanical device" and lists hardware components like the Pump, milk collection component, and charger. While it contains software and connects to an optional mobile app, it is not solely software.
Based on the provided information, the Willow Wearable Breast Pump 2.0 is not an IVD (In Vitro Diagnostic) device.
Here's why:
- Intended Use: The intended use is to "express milk from lactating women in order to collect milk from their breasts." This is a physical process performed on the body, not a test performed on a sample taken from the body to diagnose a condition.
- Device Description: The description details a mechanical device for expressing and collecting breast milk. It does not mention any components or processes related to analyzing biological samples.
- Lack of IVD Characteristics: The document does not mention any of the typical characteristics of an IVD, such as:
- Analyzing biological samples (blood, urine, tissue, etc.)
- Detecting or measuring substances in samples
- Providing diagnostic information about a disease or condition
The device is clearly intended for the physical act of milk expression and collection, which falls outside the scope of In Vitro Diagnostics.
N/A
Intended Use / Indications for Use
The Willow Wearable Breast Pump 2.0 is intended to express milk from lactating women in order to collect milk from their breasts. The device is intended for a single user.
Product codes
HGX
Device Description
The Willow Wearable Breast Pump 2.0 (Willow) is a small electric breast pump that is intended for lactating women to express and collect breast milk. Willow may be operated as a single or double pumping system. For a user to pump both breasts simultaneously, she would need to use two Willow devices at the same time, one on each breast. Willow is for use by a single user only.
Willow is a battery-powered electro-mechanical device that contains software. The device includes the following main components: Pump, milk collection component (milk bag or container), and a charger.
All milk contacting components of the device are compliant with 21 CFR 174-179.
This submission was for clearance of modifications made to the predicate device, including addition of a milk container for milk collection, updates to device firmware, inclusion of Bluetooth for connection to an optional mobile app, and a change in the flange attachment method.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Breasts
Indicated Patient Age Range
Lactating women
Intended User / Care Setting
Single user
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance data were provided to assess the device modifications and to support substantial equivalence to the predicate device. These included:
- Bench Testing: Vacuum profile testing, Maintenance of device operation and leakage assessment, Pump and milk container flow rate compatibility, Milk container ability to withstand mechanical stresses over anticipated use-life.
- Electrical Safety: IEC 60601-1+A1: 2012, IEC 60601-1-11:2015, IEC 60601-1-6: 2010 + A1:2013
- Electromagnetic Compatibility: IEC 60601-1-2:2014 (4th Edition)
- Biocompatibility: Sensitization (ISO 10993-10: 2010), Irritation (ISO 10993-10: 2010), Cytotoxicity (ISO 10993-5:2009)
- Software and Cybersecurity: Software evaluated as a minor level of concern per FDA guidance "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices." Cybersecurity evaluated per FDA guidance "Guidance for Content of Premarket Submissions for Management of Cybersecurity in Medical Devices."
The performance data demonstrate that the subject device is substantially equivalent to the predicate device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 884.5160 Powered breast pump.
(a)
Identification. A powered breast pump in an electrically powered suction device used to express milk from the breast.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is a blue square with the letters "FDA" in white, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in a smaller font.
September 6, 2019
Exploramed NC7, Inc. Steve Holmes Chief Product Officer 1975 W. El Camino Real, Suite 306 Mountain View, CA 94040
Re: K191577
Trade/Device Name: Willow Wearable Breast Pump 2.0 Regulation Number: 21 CFR 884.5160 Regulation Name: Powered Breast Pump Regulatory Class: II Product Code: HGX Dated: August 7, 2019 Received: August 8, 2019
Dear Steve Holmes:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
1
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
For Sharon M. Andrews Acting Director DHT3B: Division of Reproductive. Gynecology and Urology Devices OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K191577
Device Name Willow Wearable Breast Pump 2.0
Indications for Use (Describe)
The Willow Wearable Breast Pump 2.0 is intended to express milk from lactating women in order to collect milk from their breasts. The device is intended for a single user.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary – K191577
| Sponsor/Submitter: | Exploramed NC7, Inc
1975 W. El Camino Real, Suite 306
Mountain View, CA 94040 |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Steve Holmes
Chief Product Officer
Phone: 650 559 5805
Email: sholmes@willowpump.com |
| Date Prepared: | September 5, 2019 |
| Device Trade Name: | Willow® Wearable Breast Pump 2.0 |
| Common Name: | Breast Pump |
| Device Classification: | Class II |
| Regulation Number: | 21 CFR 884.5160 |
| Regulation Name: | Powered Breast Pump |
| Product Code: | HGX (Pump, Breast, Powered) |
| Predicate Device: | Athena Breast Pump (K161266)
The predicate device has not been subject to a design-related recall. |
| Device Description: | The Willow Wearable Breast Pump 2.0 (Willow) is a small electric breast
pump that is intended for lactating women to express and collect breast
milk. Willow may be operated as a single or double pumping system. For a
user to pump both breasts simultaneously, she would need to use two
Willow devices at the same time, one on each breast. Willow is for use by a
single user only.
Willow is a battery-powered electro-mechanical device that contains
software. The device includes the following main components: Pump, milk
collection component (milk bag or container), and a charger.
All milk contacting components of the device are compliant with 21 CFR
174-179.
This submission was for clearance of modifications made to the predicate
device, including addition of a milk container for milk collection, updates to
device firmware, inclusion of Bluetooth for connection to an optional
mobile app, and a change in the flange attachment method. |
| Indications for Use: | The Willow Wearable Breast Pump 2.0 is intended to express milk from
lactating women in order to collect milk from their breasts. The device is
intended for a single user.
The indications for use for the subject device is identical to the predicate
device. Therefore, the intended use of the subject and predicate devices is
the same (express and collect milk from breasts of lactating women). |
4
Predicate Device Comparison
| Attribute | Subject Device
Willow Wearable Breast Pump | Predicate Device
Exploramed NC7 Athena Breast
Pump |
|-------------------------------------------|--------------------------------------------------|----------------------------------------------------------|
| 510(k) number | K191577 | K161266 |
| Single User | Yes | Yes |
| Single/double pump | Single or double | Single or double |
| Media separation
(backflow protection) | Yes | Yes |
| Cycling control
mechanism | Microcontroller | Microcontroller |
| Specifications | | |
| Power supply | Li Ion battery | Li Ion battery |
| Suction levels
(stimulation) | 60 – 105 mmHg | 60 -125 mm Hg |
| Suction levels
(expression) | 60 - 245 mm Hg | 60 - 245 mm Hg |
| Cycles per second
(stimulation) | 1.5 | 1.5 |
| Cycles per second
(expression) | 1 | 1 |
| Maximum vacuum | 270 mmHg | 270 mmHg |
| Suction levels | 7 | 7 |
| User Interface | | |
| User Control | On-off Switch
Vacuum adjustment | On-off Switch
Vacuum adjustment |
| Adjustable Suction
Levels | Yes | Yes |
| Mobile Application | BLE connectivity with an optional
Mobile App | No |
| Design | Milk container and insert
Milk bag and flange | Milk bag and flange |
| Flange/Insert size | Insert: 21 mm, 24 mm, and 27 mm | Flange: 21 mm, 24 mm, and 27 mm |
| Material | | |
| Milk Container | Co-polymer polypropylene and
silicone | - |
| Flange/Insert | Polypropylene (grade changed) and
silicone | Polypropylene |
| Pump Outer Housing | Polycarbonate and Thermoplastic
polyurethane | Polycarbonate |
The subject device and predicate devices are similar in most of the technological features. However, there are a number of differences between the subject and predicate device that are described below:
- The subject device collects milk into a milk container or milk bag. The predicate device only collects milk into a milk bag.
- . The pump firmware was updated. The changes in firmware include the following:
- Improvement in volume calculation and bag full notification O
- Enhancing initial latch/early pumping experience o
- Stimulation Phase Vacuum level changed from 60-125 mmHg to 60-105 mmHg o
- The subject device includes BLE connectivity to connect the pump to an optional Mobile App.
5
- . The features for Flange attachment to pump was changed from mechanical buttons to magnetic closure.
- . Material differences.
These differences in technological characteristics do not raise different questions of safety and effectiveness.
The following performance data were provided to assess the device modifications Performance Data: and to support substantial equivalence to the predicate device:
- Bench Testing
- Vacuum profile testing. o
- Maintenance of device operation and leakage assessment. O
- Pump and milk container flow rate compatibility. O
- Milk container ability to withstand mechanical stresses over o anticipated use-life.
- Electrical Safety ●
- IEC 60601-1+A1: 2012 O
- IEC 60601-1-11:2015 O
- o IEC 60601-1-6: 2010 + A1:2013
- Electromagnetic Compatibility
- IEC 60601-1-2:2014 (4th Edition) O
- . Biocompatibility
- Sensitization (ISO 10993-10: 2010) o
- Irritation (ISO 10993-10: 2010) O
- Cytotoxicity (ISO 10993-5:2009) O
- Software and Cybersecurity ●
- Software evaluated as a minor level of concern per FDA o guidance "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices."
- O Cybersecurity evaluated per FDA guidance "Guidance for Content of Premarket Submissions for Management of Cybersecurity in Medical Devices."
Conclusion
The subject and predicate devices have the same intended use and comparable technological characteristics. The differences in technological characteristics between the subject and predicate devices do not raise different questions of safety and effectiveness. The performance data demonstrate that the subject device is substantially equivalent to the predicate device.